Antibody Conjugation and Formulation

Abstract

In an era where ultra-high antibody concentrations, high viscosities, low volumes, auto-injectors, and long storage requirements are already complex problems with the current unconjugated monoclonal antibodies on the market the formulation demands for antibody-drug conjugates (ADCs) are significant. Antibodies have historically been administered at relatively low concentrations through intravenous (IV) infusion due to their large size and the inability to formulate for oral delivery. Due to the high demands associated with IV infusion and the development of novel antibody targets and unique antibody conjugates more accessible routes of administration such as intramuscular (IM), and subcutaneous (SC) are being explored. This review will summarize various site-specific and non-site-specific antibody conjugation techniques in the context of antibody-drug conjugates (ADCs) and the demands of formulation for high concentration clinical implementation.